期刊文献+

缬沙坦治疗早期糖尿病肾病疗效观察 被引量:2

下载PDF
导出
摘要 目的观察缬沙坦对早期糖尿病肾病患者尿微量白蛋白的影响。方法将69例糖尿病肾病(DN)患者随机分为观察组(35例)和对照组(34例)。全部对象均给予常规糖尿病药物治疗,观察组加予缬沙坦80mg/d,与对照组比较8周前后尿微量白蛋白和血肌肝、尿素氮的变化。结果观察组显著优于对照组。结论血管紧张素II受体拮抗剂(缬沙坦)能够有效减少早期糖尿病肾病患者尿微量白蛋白排泄,对DN有延缓进展的作用。
出处 《中国现代药物应用》 2009年第12期143-143,共1页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献3

二级参考文献18

  • 1高鑫,左静南.实验性糖尿病大鼠早期肾脏结构和功能的改变[J].中华肾脏病杂志,1989,5(2):71-75. 被引量:17
  • 2Li L S,Kidney Int,1996年,49卷,287页 被引量:1
  • 3Fioretto P,Diabetes,1994年,43卷,1358页 被引量:1
  • 4Risau W.Mechanisms of angiogenesis[J],1997(6626). 被引量:3
  • 5Shimizu A;Kitamura H;Masuda Y.Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis,1997. 被引量:1
  • 6Yang N;Nikolic-Paterson DJ;Ng YY.Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor(MIF): potential role of MIF in regulating glucocorticoid production,1998(04). 被引量:1
  • 7Mackenzie HS;Taal MW;Luyckx VA.Adaptation to nephron loss,1999. 被引量:1
  • 8Fine LG;Orphanides C;Norman JT.Progressive renal disease: the chronic hypoxia hypothesis,1998. 被引量:1
  • 9Kang DH;Kanellis J;Hugo C.Role of the microvascular endothelium in progressive renal disease[J],2002(12). 被引量:1
  • 10Wada Y;Morioka T;Oyanagi-Tanaka Y.Impairment of vascular regeneration precedes progressive glomerulosclerosis in anti-Thy 1 glomerulonephritis[J],2002. 被引量:1

共引文献74

同被引文献18

  • 1李明子,裴海成.尾加压素Ⅱ及受体拮抗剂与糖尿病及肾脏病[J].第二军医大学学报,2007,28(7):756-757. 被引量:4
  • 2Karalliedde J, Viberti G. Proteinuria in diabetes: bystander or pathway to cardiorenal disease?[J].J Am Soc Nephrol,2010, 21(12):2020-2027. 被引量:1
  • 3Newman D J, Mattock MB, Dawnay AB, et al. Systematic review on urine albumin testing for early detection of diabetic complications[J]. Health Technol Assess,2005, 9(30):iii-vi, xiii-163. 被引量:1
  • 4Ruggenenti P, Pema A, Gherardi G, et al. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury [J].Am J Kidney Dis, 2000, 35(6): 1155-1165. 被引量:1
  • 5Gaede P, Vedel P, Larsen N, et al. Multlfactorial intervention and cardiovascular disease inpatients with type 2 diabetes [J]. N Engl J Med, 2003,348:383-393. 被引量:1
  • 6Gaede PH, Jepsen PV, Larsen JN, et al. The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes [J]. Ugeskr Laeger,165 (26): 2658-2661. 被引量:1
  • 7Gaede P, Pedersen O. Target intervention against multiple-risk markers to reduce cardiovascular disease in patients with type 2 diabetes [J]. Ann Med, 2004,36(5):355-366. 被引量:1
  • 8Pedersen O, Gaede P. Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study [J]. Metabolism, 2003,52(8 Suppl 1):19-23. 被引量:1
  • 9Schjoedt K.J, Rossing K, Juhi TR, et al. Beneficial impact of spironolaetone in diabetic nephropathy [J]. Kidney Int, 2005,68 (6): 2829-2836. 被引量:1
  • 10Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spirono- lactone on nephrotic range albuminuria in diabetic nephropathy [J]. Kidney Int, 2006,70(3):536-542. 被引量:1

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部